ICER Gives Allergan, Biohaven CGRP Inhibitors Slight Edge Over Lilly’s Reyvow
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.
You may also be interested in...
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.